TY - JOUR
T1 - Immunological Backbone of Uveal Melanoma
T2 - Is There a Rationale for Immunotherapy?
AU - Rossi, Ernesto
AU - Schinzari, Giovanni
AU - Zizzari, Ilaria Grazia
AU - Maiorano, Brigida Anna
AU - Pagliara, Monica Maria
AU - Sammarco, Maria Grazia
AU - Fiorentino, Vincenzo
AU - Petrone, Gianluigi
AU - Cassano, Alessandra
AU - Rindi, Guido
AU - Bria, Emilio
AU - Blasi, Maria Antonietta
AU - Nuti, Marianna
AU - Tortora, Giampaolo
PY - 2019/7/26
Y1 - 2019/7/26
N2 - No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
AB - No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
U2 - 10.3390/cancers11081055
DO - 10.3390/cancers11081055
M3 - Review article
C2 - 31357439
VL - 11
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 8
ER -